One of the first statements in this document points out these are not “regular guidelines” developed after thorough analysis of all the available evidence published since the last update. Instead, they are meant to provide temporary basic management pointers on how to handle different scenarios of cardiac patients in the context of the COVID-19 pandemic.<a href="https://solaci.org/en/2020/04/27/ecs-guidelines-for-covid-19-management/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) seems to be safe in low-risk patients with bicuspid aortic valve stenosis. Their hospital length of stay was very short, with zero mortality, and zero disabling stroke. Subclinical leaflet thrombosis and device durability are still unknown. The United States Food and Drug Administration (FDA) approved TAVR for low-risk patients. However,<a href="https://solaci.org/en/2020/04/27/tavr-reaches-low-risk-patients-with-bicuspid-valves/" title="Read more" >...</a>
In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy following percutaneous coronary intervention (PCI) regardless initial indications. All evidence in support of these arguments might be failing to show the risk of non-culprit lesion events in patients with acute coronary syndromes (ACS). Potent and prolonged antithrombotic therapies<a href="https://solaci.org/en/2020/04/22/are-non-culprit-lesions-really-innocent/" title="Read more" >...</a>
According to this new study presented virtually at the suspended American College of Cardiology (ACC) 2020 Scientific Session and published simultaneously in the New England Journal of Medicine (NEJM), rivaroxaban is more effective than enoxaparin in preventing venous thromboembolism during a period of immobilization after nonmajor orthopedic surgery of a lower limb. After an orthopedic<a href="https://solaci.org/en/2020/04/06/virtual-acc-2020-pronomos-rivaroxaban-superior-to-enoxaparin-in-orthopedic-surgery/" title="Read more" >...</a>
The original TWILIGHT findings in more than 9000 patients who underwent angioplasty were presented last year at TCT and showed a 3.1% absolute risk reduction in BARC 2, 3, or 5 bleeding with no increase in death, infarction, or stroke in patients who received ticagrelor and placebo compared with patients who received ticagrelor and aspirin. All patients<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-twilight-complex-ticagrelor-monotherapy-in-the-most-dangerous-angioplasties/" title="Read more" >...</a>
The 2-year outcomes in patients with severe aortic stenosis and low surgical risk continue to show a numerical benefit in favor of transcatheter aortic valve replacement (TAVR) vs. surgical replacement (CABG) for the primary end point of death, stroke or repeat hospitalization for cardiovascular reasons. However, the initially higher advantage of TAVR has been narrowing<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-partner-3-tavr-vs-cabg-in-low-risk-at-2-years/" title="Read more" >...</a>
This very interesting work leaves us with a sour taste in our mouth, as it failed to meet its primary endpoint. Using genotype to individualize treatment with a P2Y12 inhibitor in patients with acute coronary syndrome or stable patients after a scheduled angioplasty compared with conventional treatment with clopidogrel does not reduce the risk of<a href="https://solaci.org/en/2020/04/01/virtual-acc-2020-tailor-pci-gene-based-prescribing-of-clopidogrel-does-not-change-outcomes/" title="Read more" >...</a>
As a “friendly,” easy-to-read document, the new European guidelines on pulmonary embolism (PE) include an excellent summary chart with new and modified items (compared with the 2014 guidelines), and also some sort of final conclusion composed of crucial tips and contraindications that come in handy in case of emergency. Diagnosis stage In suspected high-risk PE,<a href="https://solaci.org/en/2020/03/04/what-to-do-and-what-not-to-do-in-case-of-pe-according-to-the-new-european-guidelines/" title="Read more" >...</a>
Intolerance to aspirin is relatively frequent and there is no other non-steroid anti-inflammatory medication to replace it. The new guidelines of chronic coronary syndromes make class IIb recommendations to use prasugrel or ticagrelor in aspirin-intolerant patients. This is not meant to replace dual antiaggregation therapy in aspirin intolerant patients, when needed; it is just a<a href="https://solaci.org/en/2020/03/02/alternatives-for-patients-allergic-to-aspirin/" title="Read more" >...</a>